---
title: Quadriparesis and paraparesis following chimeric antigen receptor T-cell (CART)
  therapy in children and adolescents
date: '2024-06-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38905637/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240622182853&v=2.18.0.post9+e462414
source: Blood
description: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common
  but potentially severe adverse event associated with chimeric antigen receptor T-cell
  (CART) therapy characterized by the development of acute neurologic symptoms following
  CART infusion. ICANS encompasses a wide clinical spectrum typified by mild to severe
  encephalopathy, seizures and/or cerebral edema. As more patients have been treated
  with CART new ICANS phenomenology has emerged. We present the clinical course ...
disable_comments: true
---
Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common but potentially severe adverse event associated with chimeric antigen receptor T-cell (CART) therapy characterized by the development of acute neurologic symptoms following CART infusion. ICANS encompasses a wide clinical spectrum typified by mild to severe encephalopathy, seizures and/or cerebral edema. As more patients have been treated with CART new ICANS phenomenology has emerged. We present the clinical course ...